Our results showing lower levels of aSMase in CSF from AD participants suggest that a similar approach to replace aSMase in AD may enhance Aβ42 secretion and clearance from the brain while stabilizing or repairing damaged neuronal plasma membranes. The gene discussed is SMPD1; the disease is Alzheimer disease.